Medicare and Medicaid In Brief
Executive Summary
Provenge review scheduled: The Medicare Evidence Development and Coverage Advisory Committee is scheduled to review Dendreon's novel prostate cancer vaccine Provenge (sipuleucil T) on Nov. 17. CMS says in an Aug. 31 announcement it has called the meeting to "consider the currently available evidence regarding the impact of labeled and unlabeled use of autologous cellular immunotherapy treatment on health outcomes." Provenge is approved for treating asymptomatic or minimally symptomatic prostate cancer that is metastatic and resistant to standard hormone treatment. The potential for use in earlier stages of the disease is the off-label opportunity. The review is part of a national coverage analysis for Provenge 1("The Pink Sheet," Aug. 9, 2010). The NCA recently prompted a letter from Sens. Arlen Specter, R-Penn. and John Kerry, D-Mass., who expressed concern about limiting access to Provenge among Medicare beneficiaries
You may also be interested in...
AMP Rule Withdrawal Previews Potential Issues When CMS Revisits Issue
Commenters target a variety of issues including federal upper limit requirements and impact on 340B pricing.
Part B Hospital Drug Reimbursement Set At ASP Plus 5 Percent In Final Rule
CMS had proposed an increase to ASP plus 6% for drugs used in the hospital outpatient setting in draft rule. Agency also is not moving ahead on Part B price substitution plan for drugs used in the physician office setting.
Former GPhA Head Kathleen Jaeger To Take Over As CEO Of NCPA
Jaeger takes on role at National Community Pharmacists Association on Nov. 1, 2010, as the organization works with CMS on Medicaid generic pharmacy reimbursement regulations.